Dodecafluoropentane emulsion (DDFPe) is a novel nanotechnology for oxygen delivery with therapeutic potential for hemorrhagic shock and/or traumatic brain injury (TBI). DDFPe demonstrates efficacy at smaller doses than previously tested perfluorocarbon oxygen therapeutics. This smaller dose potentially eliminates toxicities exhibited by previous oxygen therapeutics, while anti-inflammatory properties of DDFPe may alleviate damage from ischemia reperfusion injury. This mini-review summarizes our progress in developing a battle-field ready product to prevent combat death due to hemorrhagic shock and/or TBI.
This poster was presented at the National Neurotrauma Society Meeting, Snowbird, Utah, on July 11th, 2017. In this swine model of TBI, administration of DDFPe resulted in lower injury scores for spongiosis and ischemic neurons in the cerebellum as well as a decreased number of Fluoro-Jade B positive purkinje cells. This data suggests that DDFPe may play a role in mitigating secondary brain damage.
This book, published in 2017, is a very timely compilation of cutting-edge aspects of neuroprotective therapy for ischemic stroke. This book is divided into four sections, ranging from historical aspects of neuroprotection right through to the latest aspects of clinical trial design. Chapter 26 on oxygen carriers was authored by NuvOx co-founder, Jennifer Johnson, PhD. A link to excerpts is here.
Dodecafluoropentane emulsion (DDFPe), an advanced oxygen transport drug, given IV at 90-min intervals maintains viability in the penumbra during cerebral ischemia in the standard rabbit anterior stroke model. This study investigated shortened dosage schedules of DDFPe in nonstandard posterior strokes following occlusions of the posterior cerebral arteries. In the standard anterior stroke group given DDFPe, the % stroke volume, neurological assessment scores, and serum glutamate were significantly decreased vs controls (p = 0.0016, 0.008, and 0.016, respectively). In the DDFPe nonstandard posterior stroke group, %SV, NAS, and serum glutamate did not differ statistically com-pared to nonstandard controls (p= 0.82, 0.097, and 0.06, respectively). In anterior strokes, DDFPe improves recovery but not in the more severe nostandard posterior strokes. Dated: 2016
DDFPe significantly increases xenograft pO2 for up to 45 minutes via fiber-optic probe measurement. This agent may offer a novel means of transient reversal of tumor hypoxia in concert with chemoradiation. Click here to read the publication.
Hypoxia is a critical secondary injury mechanism in traumatic brain injury (TBI), and early intervention to alleviate post-TBI hypoxia may be beneficial. NVX-108, a dodecafluoropentane perfluorocarbon, was screened for its ability to increase brain tissue oxygen tension (PbtO2) when administered soon after TBI. NVX-108 caused an increase in PbtO2 following controlled cortical impact TBI in rats and should be evaluated further as a possible immediate treatment for TBI. Dated: 2016
A mouse tumor window chamber model was made to measure the amount of oxygen in tumors in mice over time. The mice are injected with NuvOx Pharma's NVX-108, and the level of oxygen in the tumors increases significantly in the next few minutes and remains elevated for the entire 63 minute monitoring period. Dated: 2015
DDFPe nanodroplets are exceptional oxygen transporters and can protect ischemic brain in stroke models 24 h without reperfusion. Current stroke therapy usually fails to reach patients because of delays following stroke onset. We tested using DDFPe to extend the time window for tissue plasminogen activator (tPA). Longer treatment windows will allow more patients more complete stroke recovery. We test DDFPe to safely extend the time window for tPA thrombolysis to 9 h after stroke. Dated: 2015